Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. (Q39486283)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

phase I clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

breast cancer surgery

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Janis Gardovskis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Janusz Jaśkiewicz

3

object named as

Janusz Jaskiewicz

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Nigel Bundred

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Janis Eglitis

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Viktor Paramonov

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Peter McCormack

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Helen Swaisland

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Maria Cavallin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Tony Parry

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

James Carmichael

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J Michael Dixon

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

13 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

949-958

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PARP inhibition: PARP1 and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Synthetic lethality: General principles, utility and detection using genetic screens in human cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9922-7

21 January 2018

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Base Excision Repair and its Role in Maintaining Genome Stability

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Poly(adenosine diphosphoribose) polymerase in peripheral blood leukocytes from normal donors and patients with malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9922-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315029%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39486283&oldid=2202922259"